Lyra Therapeutics Inc.

0.12
-0.00 (-0.08%)
At close: Apr 02, 2025, 3:59 PM
0.11
-2.80%
After-hours: Apr 02, 2025, 08:00 PM EDT

Company Description

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.

It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps.

The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Lyra Therapeutics Inc.
Lyra Therapeutics Inc. logo
Country United States
IPO Date May 1, 2020
Industry Biotechnology
Sector Healthcare
Employees 30
CEO Dr. Maria Palasis Ph.D.

Contact Details

Address:
480 Arsenal Way
Watertown, Massachusetts
United States
Website https://lyratherapeutics.com

Stock Details

Ticker Symbol LYRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001327273
CUSIP Number 55234L105
ISIN Number US55234L1052
Employer ID 00-0000000
SIC Code 3841

Key Executives

Name Position
Dr. Maria Palasis Ph.D. Chief Executive Officer, President & Director
Jason Cavalier Chief Financial Officer, Treasurer & Secretary
Ronan P. O'Brien J.D. Chief Legal Officer
Allison Nance Senior Vice President of Regulatory Affairs
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder
Dr. Elazer R. Edelman FACC, M.D., Ph.D. Vice President of Finance & Risk
Dr. Harlan W. Waksal M.D. Executive Chairman
Dr. Robert Kern M.D. Chief Clinical Advisor
Gloria Cosgrove Senior Vice President of Quality
Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs

Latest SEC Filings

Date Type Title
Mar 25, 2025 PRE 14A Filing
Mar 13, 2025 S-8 Filing
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 10, 2025 4 Filing
Jan 10, 2025 4 Filing
Jan 10, 2025 8-K Current Report
Dec 16, 2024 SC 13D/A [Amend] Filing
Dec 13, 2024 8-K Current Report